ArticleNature2019
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.
3 registry-linked trialsAbstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 406 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
406citing papers in PubMed, 3 pooled it
24.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of CSF of Patients with Glioblastomas on the Microglial Immune Profile
Role of Circulating Tumor DNA (ctDNA) in Genetic Profiling and Clinical Outcomes for Advanced Biliary Tract Cancer (BTC) Patients - A Multicenter, Prospective, Observational Epidemiology Study
Role of Circulating Tumor DNA (ctDNA) in Genetic Profiling and Clinical Outcomes for Advanced Biliary Tract Cancer (BTC) Patients - Prospective, Observational, Epidemiology Study
Who cites it
406 citing papers in PubMed, 3 syntheses or guidelines pooled it, 623 citations in OpenAlex.
- Cerebrospinal fluid ctDNA as a diagnostic and prognostic tool in gliomas: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Is There a Role for Machine Learning in Liquid Biopsy for Brain Tumors? A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Quantitative study of bioinformatics analysis on glioma: a bibliometric analysis.Frontiers in oncology · 2023Pooled it
- Tumor-derived cell-free DNA detected in cerebrospinal fluid enables minimally invasive profiling of pediatric brain tumors.The Journal of clinical investigation · 2026Trial
- Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab.Journal of cancer research and clinical oncology · 2024Trial
- Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.Cancer immunology, immunotherapy : CII · 2024Trial
- Beyond variant detection: Mismatch repair gene alterations in plasma cell-free DNA from 1,226 glioma samples, and plasma-confirmed functional deficiency in an unbiopsied pontine glioma.The journal of liquid biopsy · 2026Article
- Exploring the landscape of targetable alterations in patients with glioblastoma.Nature reviews. Clinical oncology · 2026Review
- Early experience with cerebrospinal fluid cell-free DNA molecular profiling in a neuro-oncology practice.Journal of neuro-oncology · 2026Article
- Somatic mosaicism in the brain: linking development, ageing and neurodegeneration.Nature reviews. Neurology · 2026Review
- Elevated dNTP Pool Levels Impair Homologous Recombination and Enhance Glioblastoma Sensitivity to Irradiation and Temozolomide.International journal of molecular sciences · 2026Article
- Integrating Radiogenomics and CSF-Based Liquid Biopsy Sequencing for Precision Neuro-Oncology.International journal of molecular sciences · 2026Review
- IDH-Mutant Diffuse Glioma: From Metabolic Origins to Targeted Therapy.Journal of clinical medicine · 2026Review
- Cerebrospinal fluid cell-free DNA sequencing in pediatric CNS tumors: towards liquid molecular neuropathology.Acta neuropathologica · 2026Review
- Should we optimise or revise the management of initially unresectable stage III non-small cell lung cancer: rethinking consolidation therapy.Journal of the National Cancer Center · 2026Article
- Integrated Proteomic and Metabolomic Analyses of Cerebrospinal Fluid from Pediatric Patients with Diffuse Intrinsic Pontine Glioma.International journal of molecular sciences · 2026Article
- The New Spine of Access to the Brain's Secrets: Extracellular Vesicles from Cerebrospinal Fluid Liquid Biopsies in CNS Diseases and Blood-Brain Barrier Research.Molecular neurobiology · 2026Review
- A Dual-Channel Synergistic Ultrasensitive Biosensor for Tumor Liquid Biopsy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Liquid Biopsy in Primary CNS Tumors: Bridging Biology, Technology, and Clinical Care.Molecular diagnosis & therapy · 2026Review
- Cerebrospinal Fluid in Pediatric Neuro-Oncology: Molecular Diagnosis, Disease Monitoring, and Clinical Translation.International journal of molecular sciences · 2026Review
346 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
30 authors at 3 institutions in 1 country.
Alexandra M MillerDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ronak H ShahDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elena I PentsovaDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Maryam PourmalekiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Samuel BriggsDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Natalie DistefanoDepartment of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Youyun ZhengDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anna SkakodubDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Smrutiben A MehtaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Carl CamposHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wan-Ying HsiehHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
S Duygu SelcukluCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lilan LingCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Fanli MengCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Xiaohong JingCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Aliaksandra SamoilaDepartment of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tejus A BaleDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dana W Y TsuiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Christian GrommesDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Agnes VialeCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mark M SouweidaneDepartment of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Viviane TabarDepartment of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cameron W BrennanDepartment of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anne S ReinerDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marc RosenblumDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Katherine S PanageasDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lisa M DeAngelisDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Robert J YoungDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael F BergerDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. bergerm1@mskcc.org.
Ingo K MellinghoffDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. mellingi@mskcc.org.
Memorial Sloan Kettering Cancer Center · USMolecular Oncology (United States) · USCornell University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MSPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0MMolecular Mechanisms of Drug Resistance in Primary Brain TumorsR35NS105109 · NINDS · SLOAN-KETTERING INST CAN RESEARCH · PI MELLINGHOFF, INGO K · 2018 to 2025
$4.7MNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NIH HHS 1 R35 NS105109 01NINDS NIH HHS R35 NS105109
Abstract
Diffuse gliomas are the most common malignant brain tumours in adults and include glioblastomas and World Health Organization (WHO) grade II and grade III tumours (sometimes referred to as lower-grade gliomas). Genetic tumour profiling is used to classify disease and guide therapy
Indexed as
Evolution, MolecularLiquid BiopsyMutationGenes, NeoplasmGenome, HumanGenomicsGlioblastomaGliomaHumansNeoplasm Grading
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.